NEW YORK (GenomeWeb News) — Molecular diagnostics developer Cepheid said today that it expects to report revenue of around $38 million for the fourth quarter of 2008, a dip of around 6 percent from the $40.4 million it posted a year ago.

Looking at the full year, Cepheid said it expects to report revenues of $170 million, an increase of 31 percent from its full-year 2007 revenues of $129.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.